Is the sky the limit? Valeant raises Allergan bid again
This article was originally published in Scrip
Valeant Pharmaceuticals increased the cash component of its bid for Botox and Restasis maker Allergan by nearly 50% more than its original offer to $72 per share on 30 May, bringing the deal's total potential value to almost $54bn.
You may also be interested in...
Private Company Edition: TVM, Focus/MD Anderson and RA Capital launched new venture capital funds. Also, LianBio’s $310m crossover financing, AavantiBio’s Sarepta-backed $107m series A and Sirnaomics’ $105m series D led recent VC rounds.
Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.